Hennion & Walsh Asset Management Inc. Purchases 66,528 Shares of Arcturus Therapeutics Holdings Inc. $ARCT

Hennion & Walsh Asset Management Inc. raised its position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 23.8% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 346,207 shares of the biotechnology company’s stock after purchasing an additional 66,528 shares during the period. Hennion & Walsh Asset Management Inc. owned approximately 1.22% of Arcturus Therapeutics worth $2,327,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in ARCT. Osaic Holdings Inc. boosted its holdings in shares of Arcturus Therapeutics by 51.8% in the 2nd quarter. Osaic Holdings Inc. now owns 2,163 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 738 shares in the last quarter. BNP Paribas Financial Markets raised its holdings in shares of Arcturus Therapeutics by 163.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,169 shares of the biotechnology company’s stock valued at $54,000 after buying an additional 2,586 shares in the last quarter. Mercer Global Advisors Inc. ADV purchased a new position in shares of Arcturus Therapeutics during the 4th quarter valued at about $64,000. Intech Investment Management LLC bought a new stake in Arcturus Therapeutics in the 4th quarter worth approximately $70,000. Finally, CANADA LIFE ASSURANCE Co lifted its position in Arcturus Therapeutics by 65.1% in the 4th quarter. CANADA LIFE ASSURANCE Co now owns 12,009 shares of the biotechnology company’s stock worth $73,000 after buying an additional 4,737 shares during the last quarter. Institutional investors own 94.54% of the company’s stock.

Analyst Ratings Changes

Several research analysts have commented on ARCT shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Arcturus Therapeutics in a research note on Friday, July 17th. Wall Street Zen raised shares of Arcturus Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Sunday. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $24.25.

Arcturus Therapeutics Trading Up 6.7%

ARCT stock opened at $7.52 on Wednesday. The firm’s 50-day moving average price is $6.75 and its two-hundred day moving average price is $7.39. Arcturus Therapeutics Holdings Inc. has a 12-month low of $5.50 and a 12-month high of $24.17. The stock has a market capitalization of $213.72 million, a price-to-earnings ratio of -2.27 and a beta of 2.39.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its earnings results on Thursday, August 6th. The biotechnology company reported ($0.84) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.16. The company had revenue of $2.96 million during the quarter, compared to analyst estimates of $3.11 million. Arcturus Therapeutics had a negative net margin of 317.62% and a negative return on equity of 46.54%. Equities analysts predict that Arcturus Therapeutics Holdings Inc. will post -3.55 EPS for the current year.

Arcturus Therapeutics Profile

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.